Intellectual Property India Publishes Patent Application for 'Phospholipid Ether Conjugates As Cancer-Targeting Drug Vehicles' Filed by Cellectar Biosciences, Inc.

MUMBAI, India, Nov. 21 -- Intellectual Property India has published a patent application (202518097764 A) filed by Cellectar Biosciences, Inc.Florham Park, U.S.A., on Oct. 10, for 'phospholipid ether conjugates as cancer-targeting drug vehicles.'

Inventor(s) include Longcor, Jarrod; Pinchuk, Anatoly; Hoover, Randall; and Huang, Zhongping.

The application for the patent was published on Nov. 21, under issue no. 47/2025.

According to the abstract released by the Intellectual Property India: "Disclosed herein are therapeutic compounds capable of targeting a broad range of tumor cells. The present disclosure is further directed to compositions comprising the therapeutic compounds, methods of manufacturing the therapeutic compounds, and methods of treating cancer comprising administering the therapeutic compounds."

The patent application was internationally filed on Sept. 11, 2020, under International application No.PCT/US2020/050459.

Disclaimer: Curated by HT Syndication.